HERMES PHARMA Invests US$26 milion (€25 million) for Manufacturing Site in Wolfratshausen, Germany
Introduction:
HERMES PHARMA plans to invest US$26 milion (€25 million) to construct user-friendly oral dosage development and manufacturing site in Wolfratshausen, Germany.
Features:
This investment is designed with cutting-edge machinery, expanded production and storage capabilities, and enhanced operational efficiency.
These enhancements are strategically aimed at addressing the demand for oral dosage forms that are user-friendly.
The investment will add
-
Introduction of new, high-capacity coating equipment to support the rising demand for advanced taste-masking
-
New state-of-the-art filling and packaging lines tailored for ODGs and instant drinks
-
Expansion of Good Manufacturing Practise (GMP) manufacturing space
-
Enhancement of GMP storage capacity
-
Streamlining of inventory and goods flow on the shop floor
Certainly, the soaring demand for easy-to-swallow oral dosage forms like orally disintegrating granules (ODGs), chewable tablets, lozenges, instant drinks, and effervescents has prompted efforts to incorporate these alternatives into their product portfolios.
The latest investment aims to expedite the delivery of new and enhanced user-friendly dosage forms to patients in a more efficient manner than ever before.
Specifications:
Name HERMES PHARMA
Type New Construcion
Budget US$26 milion (€25 million)
